Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease—what about mucosal healing and biomarkers? Authors' reply

LINKED CONTENT This article is linked to Biemans et al and Bertani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15745 and https://doi.org/10.1111/apt.15920

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2020-08, Vol.52 (4), p.753-754
Main Authors: Biemans, Vince B. C., Hoentjen, Frank, Pierik, Marieke J.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized
Biomarkers
Crohn Disease - drug therapy
Crohn's disease
Humans
Mucosa
Tumor Necrosis Factor-alpha
Ustekinumab - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LINKED CONTENT This article is linked to Biemans et al and Bertani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15745 and https://doi.org/10.1111/apt.15920
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.15959